SICHUAN KELUN PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.94 CNY | -0.18% |
|
-0.03% | +16.83% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 23.3B 3.22B | Sales 2025 * | 25.28B 3.5B | Capitalization | 53.99B 7.47B |
|---|---|---|---|---|---|
| Net income 2024 * | 2.83B 392M | Net income 2025 * | 3.09B 427M | EV / Sales 2024 * | 2.38 x |
| Net Debt 2024 * | 1.37B 189M | Net Debt 2025 * | 793M 110M | EV / Sales 2025 * | 2.17 x |
| P/E ratio 2024 * |
18.6
x | P/E ratio 2025 * |
17
x | Employees | 19,798 |
| Yield 2024 * |
1.78% | Yield 2025 * |
1.89% | Free-Float | 66.94% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.18% | ||
| 1 week | -0.03% | ||
| Current month | -0.03% | ||
| 1 month | +13.06% | ||
| 3 months | +27.59% | ||
| 6 months | +21.34% | ||
| Current year | +16.83% |
1 week
33.71
34.87
1 month
28.8934.87
Current year
21.6034.87
1 year
21.6034.87
3 years
14.5334.87
5 years
14.5334.87
10 years
12.2636.07
| Managers | Title | Age | Since |
|---|---|---|---|
Si Chuan Liu
CEO | Chief Executive Officer | 40 | 09-06-25 |
Ge Xin Liu
FOU | Founder | 73 | 95-12-31 |
De Gui Lai
DFI | Director of Finance/CFO | 52 | 00-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ge Xin Liu
FOU | Founder | 73 | 95-12-31 |
Guang Ji Wang
BRD | Director/Board Member | 71 | 18-04-30 |
Yun Pei Guo
BRD | Director/Board Member | 76 | 16-01-21 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.95% | 4 M€ | -2.96% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-07 | 33.94 | -0.18% | 14,567,110 |
| 24-05-06 | 34 | +0.15% | 31,598,970 |
| 24-04-30 | 33.95 | +3.41% | 23,105,040 |
End-of-day quote Shenzhen S.E., May 06, 2024
More quotes
Sichuan Kelun Pharmaceutical Co., Ltd. specializes in developing, manufacturing and marketing pharmaceuticals. Net sales break down by activity as follows:
- manufacturing and sale of pharmaceutical products (98%). Net sales break down by family of products between injectable drugs (56.9%) and other (43.1%; tablets, capsules, granules, etc.);
- other (2%).
China accounts for 94.6% of net sales.
Sector
Pharmaceuticals
Calendar
2024-05-15
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
33.94
CNY
Average target price
42.04
CNY
Spread / Average Target
+23.87%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +16.83% | 7.48B | |
| +33.43% | 700B | |
| +26.43% | 569B | |
| -5.12% | 358B | |
| +19.59% | 330B | |
| +4.89% | 287B | |
| +14.32% | 236B | |
| +5.79% | 202B | |
| -9.49% | 197B | |
| +4.26% | 161B |
- Stock Market
- Equities
- 002422 Stock